先導智能(300450.SZ):已成為全球唯一能夠提供新能源智能裝備整線解決方案的企業,連續多年市佔率居全球第一
格隆匯6月21日丨先導智能(300450.SZ)在投資者互動平台表示,公司持續推進國際化戰略和平台化戰略,公司管理層對公司未來發展有堅定的信心。截至2023年年末,公司及全資子公司累計獲得國家授權專利2347項。公司已成為全球唯一能夠提供新能源智能裝備整線解決方案的企業,連續多年市佔率居全球第一。公司核心競爭力體現在持續的國際化佈局、平台型公司的競爭優勢、鋰電池等高端製造領域的核心技術、成套設備與整體解決方案的研發能力、扁平化和信息化的管理流程體系等方面。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.